Adamis Pharmaceuticals Files IND for Product Candidate to Treat Prostate Cancer

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has recently submitted to the FDA an Investigational New Drug (IND) application for APC-100 to treat prostate cancer (PCa). Following approval by the FDA of the IND, Adamis plans to begin Phase 1/2a clinical studies with APC-100 in men with castrate resistant prostate cancer (CRPR). Each patient will be assessed for toxicity, biochemical responses (Prostate Specific Antigen), radiographic and clinical responses.

The study will start at the University of Wisconsin Carbone Cancer Center and then extend to Wayne State University Karmanos Cancer Institute. Both of these Institutions are currently named within “The Prostate Cancer Clinical Trials Consortium.” This Clinical Trials Consortium or Prostate Cancer Centers of Excellence is made up of a 13 member clinical trial research group that capitalizes on their scientific expertise and unique institutional resources in order to rapidly bring new discoveries to prostate cancer patients.